News

Inotec Secures $33 Million in Series C Financing to Accelerate US Expansion

Inotec AMD, whose product NATROX® O₂ is the leader in continuous topical oxygen therapy (cTOT) for advanced wound care, today announced the successful close of a $33 million Series C financing round. The funding, led by existing internal investors, marks a major milestone in the company’s mission to revolutionize wound management and improve patient outcomes on a global scale.